;PMID: 8194046
;source_file_1230.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:48..149] = [t:48..149]
;2)sentence:[e:150..191] = [t:150..191]
;3)section:[e:195..283] = [t:195..283]
;4)section:[e:287..372] = [t:287..372]
;5)sentence:[e:376..493] = [t:376..493]
;6)sentence:[e:494..534] = [t:494..534]
;7)sentence:[e:536..621] = [t:536..621]
;8)sentence:[e:622..782] = [t:622..782]
;9)sentence:[e:783..903] = [t:783..903]
;10)sentence:[e:904..1141] = [t:904..1141]
;11)sentence:[e:1142..1262] = [t:1142..1262]
;12)sentence:[e:1263..1527] = [t:1263..1527]
;13)sentence:[e:1528..1591] = [t:1528..1591]
;14)sentence:[e:1592..1664] = [t:1592..1664]
;15)sentence:[e:1665..1742] = [t:1665..1742]
;16)sentence:[e:1743..1996] = [t:1743..1996]
;17)section:[e:2000..2044] = [t:2000..2044]

;section 0 Span:0..43
;Cancer Genet Cytogenet  1994 May;74(1):40-9
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..12] Genet) (NNP:[13..22] Cytogenet)
        (CD:[24..28] 1994) (CC:[29..36] May;74-LRB-) (CD:[36..37] 1)
        (-RRB-:[37..38] -RRB-) (CD:[38..41] :40) (::[41..42] -) (CD:[42..43] 9)))

;sentence 1 Span:48..149
;Cytogenetic studies, ras mutation, and clinical characteristics in primary 
;myelodysplastic syndrome.
;[69..72]:gene-rna:"ras"
;[115..148]:malignancy:"primary  myelodysplastic syndrome"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[48..59] Cytogenetic) (NNS:[60..67] studies))
      (,:[67..68] ,)
      (NP (NN:[69..72] ras) (NN:[73..81] mutation))
      (,:[81..82] ,) (CC:[83..86] and)
      (NP (JJ:[87..95] clinical) (NNS:[96..111] characteristics)))
    (PP (IN:[112..114] in)
      (NP (JJ:[115..122] primary) (JJ:[124..139] myelodysplastic)
          (NN:[140..148] syndrome)))
    (.:[148..149] .)))

;sentence 2 Span:150..191
;A study on 68 Chinese patients in Taiwan.
(SENT
  (NP-HLN
    (NP (DT:[150..151] A) (NN:[152..157] study))
    (PP (IN:[158..160] on)
      (NP
        (NP (CD:[161..163] 68) (JJ:[164..171] Chinese) (NNS:[172..180] patients))
        (PP-LOC (IN:[181..183] in)
          (NP (NNP:[184..190] Taiwan)))))
    (.:[190..191] .)))

;section 3 Span:195..283
;Tien HF, Wang CH, Chuang SM, Chow JM, Lee FY, Liu MC, Chen YC, Shen MC, Lin
;DT,  Lin KH.
(SEC
  (FRAG (NNP:[195..199] Tien) (NNP:[200..202] HF) (,:[202..203] ,)
        (NNP:[204..208] Wang) (NNP:[209..211] CH) (,:[211..212] ,)
        (NNP:[213..219] Chuang) (NNP:[220..222] SM) (,:[222..223] ,)
        (NNP:[224..228] Chow) (NNP:[229..231] JM) (,:[231..232] ,)
        (NNP:[233..236] Lee) (NNP:[237..239] FY) (,:[239..240] ,)
        (NNP:[241..244] Liu) (NNP:[245..247] MC) (,:[247..248] ,)
        (NNP:[249..253] Chen) (NNP:[254..256] YC) (,:[256..257] ,)
        (NNP:[258..262] Shen) (NNP:[263..265] MC) (,:[265..266] ,)
        (NNP:[267..270] Lin) (NNP:[271..273] DT) (,:[273..274] ,)
        (NNP:[276..279] Lin) (NNP:[280..283] KH.)))

;section 4 Span:287..372
;Department of Internal Medicine, National Taiwan University Hospital, Taipei,
; R.O.C.
(SEC
  (FRAG (NNP:[287..297] Department) (IN:[298..300] of) (NNP:[301..309] Internal)
        (NNP:[310..318] Medicine) (,:[318..319] ,) (NNP:[320..328] National)
        (NNP:[329..335] Taiwan) (NNP:[336..346] University)
        (NNP:[347..355] Hospital) (,:[355..356] ,) (NNP:[357..363] Taipei)
        (,:[363..364] ,) (NNP:[366..372] R.O.C.)))

;sentence 5 Span:376..493
;Cytogenetics and clinical features were studied for 68 Chinese patients with 
;primary myelodysplastic syndrome (MDS).
;[454..486]:malignancy:"primary myelodysplastic syndrome"
;[488..491]:malignancy:"MDS"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[376..388] Cytogenetics))
      (CC:[389..392] and)
      (NP (JJ:[393..401] clinical) (NNS:[402..410] features)))
    (VP (VBD:[411..415] were)
      (VP (VBN:[416..423] studied)
        (NP-1 (-NONE-:[423..423] *))
        (PP (IN:[424..427] for)
          (NP
            (NP (CD:[428..430] 68) (JJ:[431..438] Chinese)
                (NNS:[439..447] patients))
            (PP (IN:[448..452] with)
              (NP (JJ:[454..461] primary)
                (NML
                  (NML (JJ:[462..477] myelodysplastic) (NN:[478..486] syndrome))
                  (NML (-LRB-:[487..488] -LRB-) (NN:[488..491] MDS)
                       (-RRB-:[491..492] -RRB-)))))))))
    (.:[492..493] .)))

;sentence 6 Span:494..534
;Ras mutation was analyzed in 25 of them.
;[494..497]:gene-rna:"Ras"
(SENT
  (S
    (NP-SBJ-1 (NN:[494..497] Ras) (NN:[498..506] mutation))
    (VP (VBD:[507..510] was)
      (VP (VBN:[511..519] analyzed)
        (NP-1 (-NONE-:[519..519] *))
        (PP (IN:[520..522] in)
          (NP
            (NP (CD:[523..525] 25))
            (PP (IN:[526..528] of)
              (NP (PRP:[529..533] them)))))))
    (.:[533..534] .)))

;sentence 7 Span:536..621
;Thirty-four patients (50%) had clonal chromosomal abnormalities at initial 
;analysis.
(SENT
  (S
    (NP-SBJ (CD:[536..547] Thirty-four) (NNS:[548..556] patients)
      (PRN (-LRB-:[557..558] -LRB-)
        (NP (CD:[558..560] 50) (NN:[560..561] %))
        (-RRB-:[561..562] -RRB-)))
    (VP (VBD:[563..566] had)
      (NP (JJ:[567..573] clonal) (JJ:[574..585] chromosomal)
          (NNS:[586..599] abnormalities))
      (PP-TMP (IN:[600..602] at)
        (NP (JJ:[603..610] initial) (NN:[612..620] analysis))))
    (.:[620..621] .)))

;sentence 8 Span:622..782
;The most common cytogenetic aberrations were -7, +8, 5q-, and 20q-,  which
;occurred in 11 (16.2%), seven (10.3%), five (7.4%) and three patients, 
;respectively.
;[638..661]:variation-event:"cytogenetic aberrations"
;[667..668]:variation-type:"-"
;[668..669]:variation-location:"7"
;[671..672]:variation-type:"+"
;[672..673]:variation-location:"8"
;[675..677]:variation-location:"5q"
;[677..678]:variation-type:"-"
;[684..687]:variation-location:"20q"
;[687..688]:variation-type:"-"
(SENT
  (S
    (NP-SBJ (DT:[622..625] The)
      (ADJP (RBS:[626..630] most) (JJ:[631..637] common))
       (JJ:[638..649] cytogenetic) (NNS:[650..661] aberrations))
    (VP (VBD:[662..666] were)
      (NP-PRD
        (NP
          (NP (SYM:[667..668] -) (CD:[668..669] 7))
          (,:[669..670] ,)
          (NP (SYM:[671..672] +) (CD:[672..673] 8))
          (,:[673..674] ,)
          (NP (NN:[675..677] 5q))
          (SYM:[677..678] -) (,:[678..679] ,) (CC:[680..683] and)
          (NP (NN:[684..687] 20q) (SYM:[687..688] -)))
        (,:[688..689] ,)
        (SBAR
          (WHNP-1 (WDT:[691..696] which))
          (S
            (NP-SBJ-1 (-NONE-:[696..696] *T*))
            (VP (VBD:[697..705] occurred)
              (PP-LOC (IN:[706..708] in)
                (NP (CD:[709..711] 11)
                  (PRN (-LRB-:[712..713] -LRB-)
                    (NP (CD:[713..717] 16.2) (NN:[717..718] %))
                    (-RRB-:[718..719] -RRB-))
                  (NML-2 (-NONE-:[719..719] *P*)))
                (,:[719..720] ,)
                (NP (CD:[721..726] seven)
                  (PRN (-LRB-:[727..728] -LRB-)
                    (NP (CD:[728..732] 10.3) (NN:[732..733] %))
                    (-RRB-:[733..734] -RRB-))
                  (NML-2 (-NONE-:[734..734] *P*)))
                (,:[734..735] ,)
                (NP (CD:[736..740] five)
                  (PRN (-LRB-:[741..742] -LRB-)
                    (NP (CD:[742..745] 7.4) (NN:[745..746] %))
                    (-RRB-:[746..747] -RRB-))
                  (NML-2 (-NONE-:[747..747] *P*)))
                (CC:[748..751] and)
                (NP (CD:[752..757] three)
                  (NML-2 (NNS:[758..766] patients))))
              (,:[766..767] ,)
              (ADVP (RB:[769..781] respectively)))))))
    (.:[781..782] .)))

;sentence 9 Span:783..903
;The incidence of -7 was higher and that of 5q- lower in our  patients than in
;patients from most other geographic areas.
;[800..801]:variation-type:"-"
;[801..802]:variation-location:"7"
;[826..828]:variation-location:"5q"
(SENT
  (S
    (S
      (NP-SBJ=2
        (NP (DT:[783..786] The) (NN:[787..796] incidence))
        (PP (IN:[797..799] of)
          (NP (SYM:[800..801] -) (CD:[801..802] 7))))
      (VP (VBD:[803..806] was)
        (ADJP-PRD=1
          (ADJP (JJR:[807..813] higher))
          (PP-3 (-NONE-:[813..813] *RNR*)))
        (PP-4 (-NONE-:[813..813] *RNR*))))
    (CC:[814..817] and)
    (S
      (NP-SBJ=2
        (NP (DT:[818..822] that))
        (PP (IN:[823..825] of)
          (NP (NN:[826..828] 5q) (SYM:[828..829] -))))
      (ADJP-PRD=1
        (ADJP (JJR:[830..835] lower))
        (PP-3 (-NONE-:[835..835] *RNR*)))
      (PP-4 (-NONE-:[835..835] *RNR*)))
    (PP-4 (IN:[836..838] in)
      (NP (PRP$:[839..842] our) (NNS:[844..852] patients)))
    (PP-3 (IN:[853..857] than)
      (PP (IN:[858..860] in)
        (NP
          (NP (NNS:[861..869] patients))
          (PP (IN:[870..874] from)
            (NP (JJS:[875..879] most) (JJ:[880..885] other)
                (JJ:[886..896] geographic) (NNS:[897..902] areas))))))
    (.:[902..903] .)))

;sentence 10 Span:904..1141
;The 17 patients with  multiple chromosomal abnormalities had a significantly
;shorter median survival  (9 months) than the 34 patients with normal
;karyotype (33 months) and the 17  patients with patients with single
;anomalies (26 months).
(SENT
  (S
    (NP-SBJ
      (NP (DT:[904..907] The) (CD:[908..910] 17) (NNS:[911..919] patients))
      (PP (IN:[920..924] with)
        (NP (JJ:[926..934] multiple) (JJ:[935..946] chromosomal)
            (NNS:[947..960] abnormalities))))
    (VP (VBD:[961..964] had)
      (NP
        (NP (DT:[965..966] a)
          (ADJP (RB:[967..980] significantly) (JJR:[981..988] shorter))
          (JJ:[989..995] median) (NN:[996..1004] survival)
          (PRN (-LRB-:[1006..1007] -LRB-)
            (NP (CD:[1007..1008] 9) (NNS:[1009..1015] months))
            (-RRB-:[1015..1016] -RRB-)))
        (PP (IN:[1017..1021] than)
          (NP
            (NP
              (NP (DT:[1022..1025] the) (CD:[1026..1028] 34)
                  (NNS:[1029..1037] patients))
              (PP (IN:[1038..1042] with)
                (NP (JJ:[1043..1049] normal) (NN:[1050..1059] karyotype)))
              (PRN (-LRB-:[1060..1061] -LRB-)
                (NP (CD:[1061..1063] 33) (NNS:[1064..1070] months))
                (-RRB-:[1070..1071] -RRB-)))
            (CC:[1072..1075] and)
            (NP
              (NP (DT:[1076..1079] the) (CD:[1080..1082] 17)
                  (NNS:[1084..1092] patients))
              (PP (IN:[1093..1097] with)
                (NP
                  (NP (NNS:[1098..1106] patients))
                  (PP (IN:[1107..1111] with)
                    (NP (JJ:[1112..1118] single) (NNS:[1119..1128] anomalies)))))
              (PRN (-LRB-:[1129..1130] -LRB-)
                (NP (CD:[1130..1132] 26) (NNS:[1133..1139] months))
                (-RRB-:[1139..1140] -RRB-)))))))
    (.:[1140..1141] .)))

;sentence 11 Span:1142..1262
;Evolution to acute  leukemia occurred in 20 patients (29%) after a median
;interval of 8 months  following the diagnosis.
;[1155..1170]:malignancy:"acute  leukemia"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1142..1151] Evolution))
      (PP (TO:[1152..1154] to)
        (NP (JJ:[1155..1160] acute) (NN:[1162..1170] leukemia))))
    (VP (VBD:[1171..1179] occurred)
      (PP-LOC (IN:[1180..1182] in)
        (NP (CD:[1183..1185] 20) (NNS:[1186..1194] patients)
          (PRN (-LRB-:[1195..1196] -LRB-)
            (NP (CD:[1196..1198] 29) (NN:[1198..1199] %))
            (-RRB-:[1199..1200] -RRB-))))
      (PP-TMP (IN:[1201..1206] after)
        (NP
          (NP
            (NP (DT:[1207..1208] a) (JJ:[1209..1215] median)
                (NN:[1216..1224] interval))
            (PP (IN:[1225..1227] of)
              (NP (CD:[1228..1229] 8) (NNS:[1230..1236] months))))
          (VP (VBG:[1238..1247] following)
            (NP (DT:[1248..1251] the) (NN:[1252..1261] diagnosis))))))
    (.:[1261..1262] .)))

;sentence 12 Span:1263..1527
;Patients with multiple cytogenetic changes at initial  analysis or in
;subsequent studies had a significantly higher frequency of acute 
;transformation than others (55% vs. 18.6%, p = 0.007); the same was not true
;if  only the data of initial study were considered.
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NNS:[1263..1271] Patients))
        (PP (IN:[1272..1276] with)
          (NP
            (NP (JJ:[1277..1285] multiple) (JJ:[1286..1297] cytogenetic)
                (NNS:[1298..1305] changes))
            (PP-TMP
              (PP (IN:[1306..1308] at)
                (NP (JJ:[1309..1316] initial) (NN:[1318..1326] analysis)))
              (CC:[1327..1329] or)
              (PP (IN:[1330..1332] in)
                (NP (JJ:[1333..1343] subsequent) (NNS:[1344..1351] studies)))))))
      (VP (VBD:[1352..1355] had)
        (NP
          (NP (DT:[1356..1357] a)
            (ADJP (RB:[1358..1371] significantly) (JJR:[1372..1378] higher))
            (NN:[1379..1388] frequency))
          (PP (IN:[1389..1391] of)
            (NP (JJ:[1392..1397] acute) (NN:[1399..1413] transformation)))
          (PP (IN:[1414..1418] than)
            (NP (NNS:[1419..1425] others))))
        (PRN (-LRB-:[1426..1427] -LRB-)
          (FRAG
            (NP
              (NP (CD:[1427..1429] 55) (NN:[1429..1430] %))
              (PP (IN:[1431..1434] vs.)
                (NP (CD:[1435..1439] 18.6) (NN:[1439..1440] %))))
            (,:[1440..1441] ,)
            (S
              (NP-SBJ (NN:[1442..1443] p))
              (VP (SYM:[1444..1445] =)
                (NP (CD:[1446..1451] 0.007)))))
          (-RRB-:[1451..1452] -RRB-))))
    (::[1452..1453] ;)
    (S
      (NP-SBJ (DT:[1454..1457] the) (JJ:[1458..1462] same))
      (VP (VBD:[1463..1466] was) (RB:[1467..1470] not)
        (ADJP-PRD (JJ:[1471..1475] true))
        (SBAR-ADV (IN:[1476..1478] if)
          (S
            (NP-SBJ-1
              (NP
                (ADVP (RB:[1480..1484] only))
                (DT:[1485..1488] the) (NNS:[1489..1493] data))
              (PP (IN:[1494..1496] of)
                (NP (JJ:[1497..1504] initial) (NN:[1505..1510] study))))
            (VP (VBD:[1511..1515] were)
              (VP (VBN:[1516..1526] considered)
                (NP-1 (-NONE-:[1526..1526] *))))))))
    (.:[1526..1527] .)))

;sentence 13 Span:1528..1591
;Serial cytogenetic studies are  important in patient follow-up.
(SENT
  (S
    (NP-SBJ (JJ:[1528..1534] Serial) (JJ:[1535..1546] cytogenetic)
            (NNS:[1547..1554] studies))
    (VP (VBP:[1555..1558] are)
      (ADJP-PRD (JJ:[1560..1569] important))
      (PP (IN:[1570..1572] in)
        (NP (NN:[1573..1580] patient) (VB:[1581..1587] follow)
            (HYPH:[1587..1588] -) (RP:[1588..1590] up))))
    (.:[1590..1591] .)))

;sentence 14 Span:1592..1664
;N-ras mutation was detected in 5 (20%) of 25  patients within the study.
;[1592..1597]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-1 (NN:[1592..1597] N-ras) (NN:[1598..1606] mutation))
    (VP (VBD:[1607..1610] was)
      (VP (VBN:[1611..1619] detected)
        (NP-1 (-NONE-:[1619..1619] *))
        (PP-LOC (IN:[1620..1622] in)
          (NP
            (NP (CD:[1623..1624] 5)
              (PRN (-LRB-:[1625..1626] -LRB-)
                (NP (CD:[1626..1628] 20) (NN:[1628..1629] %))
                (-RRB-:[1629..1630] -RRB-)))
            (PP (IN:[1631..1633] of)
              (NP
                (NP (CD:[1634..1636] 25) (NNS:[1638..1646] patients))
                (PP (IN:[1647..1653] within)
                  (NP (DT:[1654..1657] the) (NN:[1658..1663] study)))))))))
    (.:[1663..1664] .)))

;sentence 15 Span:1665..1742
;There was no correlation between the gene mutation  and acute
;transformation.
;[1702..1706]:gene-rna:"gene"
(SENT
  (S
    (NP-SBJ (EX:[1665..1670] There))
    (VP (VBD:[1671..1674] was)
      (NP-PRD
        (NP (DT:[1675..1677] no) (NN:[1678..1689] correlation))
        (PP (IN:[1690..1697] between)
          (NP
            (NP (DT:[1698..1701] the) (NN:[1702..1706] gene)
                (NN:[1707..1715] mutation))
            (CC:[1717..1720] and)
            (NP (JJ:[1721..1726] acute) (NN:[1727..1741] transformation))))))
    (.:[1741..1742] .)))

;sentence 16 Span:1743..1996
;But combing the data of N-ras mutation and  cytogenetics, patients with
;either the N-ras mutation or clonal chromosomal  abnormalities were at
;significantly higher risk for developing acute leukemia  than those with
;neither of the changes (77% vs. 25%).
;[1767..1772]:gene-rna:"N-ras"
;[1826..1831]:gene-rna:"N-ras"
;[1927..1941]:malignancy:"acute leukemia"
(SENT
  (S (CC:[1743..1746] But)
    (S-ADV
      (NP-SBJ (-NONE-:[1746..1746] *))
      (VP (VBG:[1747..1754] combing)
        (NP
          (NP (DT:[1755..1758] the) (NNS:[1759..1763] data))
          (PP (IN:[1764..1766] of)
            (NP
              (NP (NN:[1767..1772] N-ras) (NN:[1773..1781] mutation))
              (CC:[1782..1785] and)
              (NP (NNS:[1787..1799] cytogenetics)))))))
    (,:[1799..1800] ,)
    (NP-SBJ
      (NP (NNS:[1801..1809] patients))
      (PP (IN:[1810..1814] with)
        (NP (CC:[1815..1821] either)
          (NP (DT:[1822..1825] the) (NN:[1826..1831] N-ras)
              (NN:[1832..1840] mutation))
          (CC:[1841..1843] or)
          (NP (JJ:[1844..1850] clonal) (JJ:[1851..1862] chromosomal)
              (NNS:[1864..1877] abnormalities)))))
    (VP (VBD:[1878..1882] were)
      (PP-PRD (IN:[1883..1885] at)
        (NP
          (NP
            (ADJP (RB:[1886..1899] significantly) (JJR:[1900..1906] higher))
            (NN:[1907..1911] risk))
          (PP (IN:[1912..1915] for)
            (S-NOM
              (NP-SBJ (-NONE-:[1915..1915] *))
              (VP (VBG:[1916..1926] developing)
                (NP (JJ:[1927..1932] acute) (NN:[1933..1941] leukemia)))))
          (PP (IN:[1943..1947] than)
            (NP
              (NP (DT:[1948..1953] those))
              (PP (IN:[1954..1958] with)
                (NP
                  (NP (DT:[1959..1966] neither))
                  (PP (IN:[1967..1969] of)
                    (NP (DT:[1970..1973] the) (NNS:[1974..1981] changes)
                      (PRN (-LRB-:[1982..1983] -LRB-)
                        (NP
                          (NP (CD:[1983..1985] 77) (NN:[1985..1986] %))
                          (PP (IN:[1987..1990] vs.)
                            (NP (CD:[1991..1993] 25) (NN:[1993..1994] %))))
                        (-RRB-:[1994..1995] -RRB-)))))))))))
    (.:[1995..1996] .)))

;section 17 Span:2000..2044
;PMID: 8194046 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2000..2004] PMID) (::[2004..2005] :) (CD:[2006..2013] 8194046)
        (NN:[2014..2015] -LSB-) (NNP:[2015..2021] PubMed) (::[2022..2023] -)
        (NN:[2024..2031] indexed) (IN:[2032..2035] for)
        (NNP:[2036..2044] MEDLINE-RSB-)))
